20 citations
,
June 2019 in “JAAD Case Reports” Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
14 citations
,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
25 citations
,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
July 2025 in “The Egyptian Journal of Hospital Medicine” Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
March 2022 in “Nepal Journal of Dermatology Venereology & Leprology” Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
1 citations
,
January 2026 in “Dermatology Reports” Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
4 citations
,
December 2024 in “Archives of Dermatological Research”
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
November 2025 in “Journal of Investigative Dermatology” Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.